Advertisement
UK markets close in 6 hours 53 minutes
  • FTSE 100

    8,148.67
    +27.47 (+0.34%)
     
  • FTSE 250

    20,284.27
    +89.80 (+0.44%)
     
  • AIM

    767.98
    +3.61 (+0.47%)
     
  • GBP/EUR

    1.1798
    -0.0002 (-0.02%)
     
  • GBP/USD

    1.2699
    +0.0014 (+0.11%)
     
  • Bitcoin GBP

    47,820.21
    -1,492.88 (-3.03%)
     
  • CMC Crypto 200

    1,310.00
    -24.92 (-1.87%)
     
  • S&P 500

    5,509.01
    +33.92 (+0.62%)
     
  • DOW

    39,331.85
    +162.33 (+0.41%)
     
  • CRUDE OIL

    82.97
    +0.16 (+0.19%)
     
  • GOLD FUTURES

    2,355.50
    +22.10 (+0.95%)
     
  • NIKKEI 225

    40,580.76
    +506.07 (+1.26%)
     
  • HANG SENG

    17,978.57
    +209.43 (+1.18%)
     
  • DAX

    18,255.58
    +91.52 (+0.50%)
     
  • CAC 40

    7,598.59
    +60.30 (+0.80%)
     

Hologic Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags

Hologic (NASDAQ:HOLX) Second Quarter 2024 Results

Key Financial Results

  • Revenue: US$1.02b (flat on 2Q 2023).

  • Net income: US$169.9m (down 22% from 2Q 2023).

  • Profit margin: 17% (down from 21% in 2Q 2023).

  • EPS: US$0.72 (down from US$0.88 in 2Q 2023).

earnings-and-revenue-history
earnings-and-revenue-history

All figures shown in the chart above are for the trailing 12 month (TTM) period

Hologic Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 8.9%.

Looking ahead, revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.

ADVERTISEMENT

Performance of the American Medical Equipment industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

It's still necessary to consider the ever-present spectre of investment risk. We've identified 2 warning signs with Hologic, and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.